Menu
← Oncology Approval Tracker
FDA DECISION ·
Inqovi
decitabine + cedazuridine · Astex Pharmaceuticals
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with myelodysplastic syndromes, including previously treated or untreated, de novo or secondary disease in specified subtypes and intermediate-1, intermediate-2 or high-risk groups, including chronic myelomonocytic leukemia.
LAMPGEN ANALYSIS
Why it matters
Paired decitabine with cedazuridine to make oral decitabine exposure feasible.
What research teams should watch
Plan oral adherence checks and blood counts and avoid interchanging this regimen with IV decitabine mid-cycle.
PRIMARY RECORDS